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BACKGROUND: Our study evaluated the association between body mass index (BMI) and absolute lymphocyte count (ALC) in
breast cancer patients and healthy females. Additionally, we determined the prognostic value of these factors in breast cancer.
METHODS: We retrospectively identified 1225 primary invasive breast cancer patients and 35,991 healthy females. Factors
including BMI and complete blood count associated with disease-free survival (DFS) were assessed using a multi-variable Cox
proportional hazard model.
RESULTS: BMI and ALC were positively correlated in breast cancer patients and healthy females (both P < 0.001). In multi-variable
analysis, overweight or obese participants had worse DFS (hazards ratio [HR], 1.98; 95% confidence interval [CI], 1.34–2.92; P=
0.001) than underweight or normal-weight individuals, but patients with high ALC had better DFS than those with low ALC (HR,
0.43; 95% CI, 0.29–0.65; P < 0.001). After risk stratification according to BMI/ALC, high-risk patients with high BMI/low ALC had worse
DFS than others (HR, 2.48; 95% CI, 1.70–3.62; P < 0.001).
CONCLUSIONS: BMI and ALC were positive correlated, but their effect on breast cancer prognosis was opposite. Patients with high
BMI/low ALC had worse DFS than others. Underlying mechanisms for effect of BMI/ALC on breast cancer prognosis should be
studied in the future.
British Journal of Cancer (2021) 125:119–125; https://doi.org/10.1038/s41416-021-01391-0
BACKGROUND
The global prevalence of breast cancer has substantially increased
over recent decades.1 In South Korea, breast cancer is one of the
most common malignancies among females, accounting for
>2000 deaths in 2016.2 Since breast cancer is a heterogenic
disease with several biological characteristics, various factors such
as hormone receptors, human epidermal growth factor receptor 2
(HER2), grade and Ki-67 labelling index (LI) affect disease
prognosis.3,4 Currently, significant efforts are being made to
develop methods for the accurate prediction of breast cancer
prognosis.
Obesity is another major global health concern; in South Korea,
>60% women aged >40 years are overweight or obese.5 Obesity is
an important risk factor for diabetes, cardiovascular disease and
kidney disease; it has also been recently recognised as a risk factor
for breast cancer.6 Although hormones, adipocytokines and
inflammatory cytokines have been identified as potential media-
tors, the biological mechanisms that explain the association
between obesity and breast cancer survival have not been
conclusively established.7 Body mass index (BMI), calculated using
body weight and height, is the most widely used measure for the
degree of obesity.8
Inflammatory cells have an important role in breast cancer
progression.9 Several parameters such as tumour-infiltrating
lymphocytes (TILs) and neutrophil-to-lymphocyte ratio (NLR) can
be used to assess immune response. Among them, peripheral
blood cell count has been widely used as it is easy and cost-
effective. Lymphocytes, including natural killer cells, T cells and B
cells, are types of white blood cells (WBCs) that are found in the
vertebrate immune system.10 T lymphocytes, involved in adaptive
immunity, play a key role in tumour-specific immune response.11
Several researchers have suggested that an association
between BMI and immune response are closely related.12
However, the clinical significance of this relationship has not
been assessed in breast cancer patients. Therefore, our study
aimed to identify the association between BMI and peripheral
inflammatory cells in breast cancer patients and healthy females.
Furthermore, we determined the effect of BMI and peripheral
inflammatory cells on the prognosis of breast cancer patients.
METHODS
Study population
We retrospectively identified 1225 primary invasive breast cancer
patients from the Gangnam Severance Hospital breast cancer
registry registered between January 2009 and December 2015.
Patients’ clinicopathologic information was extracted from their
medical records. All patients were South Korean; patients from
western countries were excluded owing to different BMI criteria,
and Asian patients with non-Korean parentage were not included
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in the registry. Patients underwent breast cancer surgery as
curative treatment and received adjuvant therapy if needed.
Patients who had received neoadjuvant chemotherapy were
excluded as accurate evaluation of surgical pathology and disease
stage was difficult in these patients. Patients with de novo stage IV
cancer were also excluded.
Further, 35,991 healthy women were included from the
Gangnam Severance Health Promotion Center registry between
January 2007 and July 2020 to reconfirm the association between
BMI and absolute lymphocyte count (ALC). Data on body weight,
height and complete blood count (CBC) were collected. All
women were South Korean and had never been diagnosed with or
treated for malignant disease. Patients and healthy females
excluded from the study were summarised in Supplementary
Fig. S1.
Our study was approved by the institutional review board of
Gangnam Severance Hospital (approval number: 3-2020-0207),
which waived the requirement for written informed consent
owing to the retrospective study design.
Body mass index
Body weight and height of breast cancer patients were obtained
on their first visit. If these were not measured at the first visit,
measurements taken after admission for operation were used. All
measurements were made prior to any treatment for breast
cancer. The body weight and height of all healthy females were
measured at their routine health examination. BMI was calculated
as body weight in kilograms divided by the square of height in
meters, defined by the World Health Organization (WHO).8
Participants were categorised using BMI cut-offs given in the
WHO-Asia-Pacific classification.13 According to the Asian stan-
dards, people with BMI < 18.5 kg/m2 are considered underweight,
and those with BMI ≥ 23.0 kg/m2 are considered overweight
or obese.
Complete blood count
Peripheral venous blood samples were collected from all breast
cancer patients for preoperative evaluation prior to any treatment
for breast tumour. For healthy females, same samples were
obtained at their health check-up to evaluate haemoglobin levels
and white blood cell counts. Venous blood was collected using 15
ml polypropylene tubes containing 10% ethylenediaminetetraa-
cetic acid as an anticoagulant. All blood cell counts including WBC
count, absolute neutrophil count (ANC), ALC, platelet count and
monocyte count were assessed at the same institutional
laboratory. NLR was calculated by dividing the absolute number
of neutrophils by the absolute number of lymphocytes. Patients
with WBC count ≥ 20.0 × 103/µL were excluded from study due to
the possibility of abnormal conditions including infectious disease
at the time of examination. For risk stratification according to ALC,
patients were divided into low and high groups based on the
median value of ALC in the breast cancer cohort.
Statistical analysis
The primary endpoint was disease-free survival (DFS), and
additional analysis was performed for estimating overall survival
(OS) as the secondary endpoint. DFS was defined as the time
period between breast cancer surgery and tumour recurrence,
secondary malignancy or any cause of death. Contralateral breast
cancer was classified as a secondary malignancy and not
metastasis. OS was defined as the time period from breast cancer
surgery to death due to any reason. Statistical analyses were
performed using SPSS version 25.0 (IBM Inc., Armonk, NY, USA).
Difference between the groups was evaluated by the Chi-square
test for categorical data and one-way ANOVA for continuous
variables, after confirmation by Levene’s test for equality of
variances. Kaplan–Meier survival estimates were used to compare
DFS, and the group differences in the survival curves were
analysed using the log-rank test. Univariable and multi-variable
Cox proportional hazard models were used to identify variables
associated with DFS and OS and perform subgroup analysis with
HR and corresponding 95% CI. All statistical tests were two sided,
and a P-value <0.050 was considered statistically significant.
RESULTS
Association between BMI and ALC
In the breast cancer cohort, ALC was positive correlated with BMI.
The average ALC was 1.81 × 103/µL; ALC was the lowest in
underweight patients and the highest in overweight or obese
patients (P < 0.001; Fig. 1a). WBC, platelet count and monocyte
count was increased in patients with overweight or obese
compared to patients with normal weight. (WBC, P < 0.001;
platelet, P < 0.001; monocyte, P= 0.001; Supplementary Fig. S2).
However, ANC was not correlated with BMI (P= 0.073). NLR was
significantly lower in overweight or obese patients than in
underweight patients (P= 0.025), but there was no significant
difference compared with the NLR of normal-weight patients (P=
0.641).
Next, we analysed CBC according to BMI in healthy females to
compare results with those of breast cancer patients. The average
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Fig. 1 Boxplot comparing ALC according to BMI: a ALC according to BMI in breast cancer patients, b ALC according to BMI in healthy females.
ALC absolute lymphocyte count, BMI body mass index. *P < 0.050.
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body weight. 38.2% women were overweight or obese. In the
healthy female cohort, BMI and ALC were also positively
correlated. ALC was significantly higher in overweight or obese
women than in underweight and normal-weight women (P <
0.001; Fig. 1b). The average ALC for healthy females was 1.89 ×
103/µL. Other blood cell counts such as WBC, platelet count,
monocyte count and ANC also had a positive correlation with BMI
(all P < 0.001; Supplementary Fig. S3). NLR was lower in overweight
or obese women than in normal-weight or underweight women
(P < 0.001). In addition, healthy females had significantly higher
ALC than breast cancer patients (Supplementary Table S1). In
contrast, WBC and ANC were higher in breast cancer patients than
healthy females. There was no statistical difference in platelet and
monocyte between the two groups.
Baseline characteristics of breast cancer patients
Table 1 summarises the clinicopathologic characteristics of
patients according to BMI. There were 51.4% overweight or obese
patients and 4% underweight patients. The average patient age
was 51.4 years; the average age of patients tended to increase
with the increasing BMI. Additionally, a high proportion of patients
with high BMI had tumours measuring >20mm. Other features
including grade, oestrogen receptor (ER)/progesterone receptor
(PR)/HER2 status, Ki-67 LI, and the number of positive axillary
lymph nodes did not differ with BMI. Type of breast and axillary
surgery and adjuvant therapy also did not differ with BMI
(Supplementary Table S2).
BMI and ALC as prognostic factors for DFS and OS
The 5-year DFS for all patients was 91.9%. The 5-year distant
recurrence and locoregional recurrence rates were 3.7% and 2.0%,
respectively. The median follow-up period was 70 months. There
were 152 events in 126 patients during follow-up. There were 87
recurrence, 51 secondary primary malignancy and 14 death
events. Two events of recurrence or secondary malignancy
occurred together in 14 patients, and two patients died without
any recurrence and secondary tumour. Six patients developed
contralateral breast cancer. Details of disease events have been
summarised in Supplementary Table S3. For the analysis, BMI was
divided into three groups—underweight (<18.5 kg/m2), normal
Table 1. Clinicopathologic features of breast cancer patients.
Body mass index, kg/m2 (%) P-value
All patients <18.5 18.5–23.0 ≥23.0
Total 1,225 (100) 49 (4.0) 546 (44.6) 630 (51.4)
Age, average (range), years 51.4 (24–87) 43.9 (26–67) 48.5 (24–87) 54.6 (28–87) <0.001
Histologic grade 0.157
Low 250 (20.7) 11 (22.4) 125 (22.9) 114 (18.1)
Intermediate 609 (50.4) 20 (40.8) 260 (47.6) 329 (52.2)
High 350 (28.5) 18 (36.7) 155 (28.4) 177 (28.1)
Unknown 16 (1.3) 0 (0.0) 6 (1.1) 10 (1.6)
Nuclear grade 0.263
Low 122 (10.0) 8 (16.3) 61 (11.2) 53 (8.4)
Intermediate 621 (50.7) 24 (49.0) 267 (48.9) 330 (52.4)
High 467 (38.1) 17 (34.7) 212 (38.8) 238 (37.8)
Unknown 15 (1.2) 0 (0.0) 6 (1.1) 9 (1.4)
Oestrogen receptor 0.778
Negative 355 (29.0) 12 (24.5) 159 (29.1) 184 (29.2)
Positive 870 (71.0) 37 (75.5) 387 (70.7) 446 (70.8)
Progesterone receptor 0.726
Negative 473 (38.6) 18 (36.7) 205 (37.5) 250 (39.7)
Positive 752 (61.3) 31 (63.3) 341 (62.5) 380 (60.3)
HER2 0.921
Negative 873 (71.2) 34 (69.4) 391 (71.5) 448 (71.1)
Positive 306 (25.0) 12 (24.5) 133 (24.5) 161 (25.6)
Unknown 46 (3.8) 3 (6.1) 22 (4.0) 21 (3.3)
Ki-67 LI, % 0.370
<14 671 (54.8) 27 (54.0) 287 (52.5) 357 (56.7)
≥14 554 (45.2) 22 (44.9) 259 (47.4) 273 (43.3)
Tumour size, mm 0.001
≤20 801 (65.4) 36 (73.5) 385 (70.5) 380 (60.3)
>20 424 (34.6) 13 (26.5) 161 (29.5) 250 (39.7)
Positive lymph node, count 0.216
0 842 (68.7) 40 (81.6) 373 (68.3) 429 (68.1)
1–3 296 (24.2) 6 (12.2) 139 (25.5) 151 (24.0)
≥4 87 (7.1) 3 (6.1) 34 (6.2) 50 (7.9)
HER2 human epidermal growth factor receptor 2, LI labelling index.
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weight (18.5–23.0 kg/m2) and overweight or obese (≥23.0 kg/m2),
and continuous variables were used for blood cell counts. In
univariable analysis, overweight or obesity, but not underweight,
was a risk factor for DFS (hazards ratio [HR], 1.57; 95% confidence
interval [CI], 1.09–2.26; P= 0.016; Table 2). Among blood cell
counts, patients with high ALC had significantly better DFS than
those with low ALC (HR, 0.52; 95% CI, 0.37–0.74; P < 0.001). NLR
was also statistically significant (P= 0.001), but the associated HR
was 1.08, suggesting minimal impact on prognosis. Other known
prognostic factors including histologic grade, ER/PR/HER2 status,
Ki-67 LI, tumour size and the number of positive lymph nodes (≥4)
were also significant in univariable analysis. In multi-variable
analysis, high BMI was associated with worse DFS (HR, 1.98; 95%
CI, 1.34–2.92; P= 0.001) and high ALC was a good prognostic
factor (HR, 0.43; 95% CI, 0.29–0.65; P < 0.001). However, excluding
large tumour size (>20mm; HR, 1.47; 95% CI, 1.00–2.18; P= 0.050)
and high Ki-67 LI (HR, 1.94; 95% CI, 1.22–3.07; P= 0.005), other
factors were not significant in multi-variable analysis. The
Kaplan–Meier survival curves also revealed that the high BMI
group had worse DFS than the normal and underweight groups
(log-rank P= 0.025; Supplementary Fig. S4A). Based on the
median ALC of 1.74 × 103/uL in the breast cancer cohort, we
divided patients into the low ALC group (N= 615) and the high
ALC group (N= 610). Patients with high ALC had better DFS than
those with low ALC according to the Kaplan–Meier survival
analysis (log-rank P= 0.018; Supplementary Fig. S4B). However,
BMI and ALC were not risk factors for OS (Supplementary Table S4).
Ki-67 LI and tumour size were the only prognostic factors
associated with OS in multi-variable analysis.
Risk stratification according to BMI/ALC
We scored patients according to BMI/ALC and divided them into
two risk stratification groups (low and high). If patients were
overweight or obese and had low ALC, they were classified into
the high-risk group (N= 258). Conversely, if patients were normal
or underweight or had high ALC, they were classified into the low-
risk group (N= 967). The Kaplan–Meier survival curves showed
that the high-risk group had poorer prognosis than the low-risk
group (log-rank P < 0.001; Fig. 2). The high-risk group also had
worse DFS than the low-risk group according to the multi-variable
Cox regression hazard model (HR, 2.48; 95% CI, 1.70–3.62; P <
0.001; Table 3). However, OS did not differ between the risk
stratification groups (log-rank P= 0.528; Supplementary Fig. S5).
In the subgroup analysis, BMI/ALC was a significant risk factor in
both young (≤50 yrs) and old (>50 yrs) breast cancer patients
(young: HR, 0.38; 95% CI, 0.22–0.63; P < 0.001; old: HR, 0.47; 95% CI,
0.29–0.78; P= 0.003; Fig. 3). In addition, the low-risk group had
significantly better DFS for HER2-positive tumour than the high-
risk group (HR, 0.31; 95% CI, 0.17–0.58; P < 0.001). There was also a
difference in DFS for ER-positive/HER2-negative breast cancer
between groups (HR, 0.39; 95% CI, 0.23–0.69; P= 0.001). However,
DFS for triple-negative breast cancer did not significantly differ
between groups (P= 0.244), although the HRs were different.
Furthermore, the BMI/ALC risk groups were better validated for
early breast cancer than for advanced breast cancer (stage I: HR,
0.44; 95% CI, 0.23–0.84; P= 0.012; stage II: HR, 0.38; 95% CI,
0.24–0.63; P < 0.001).
DISCUSSION
Our study found that BMI and ALC were positive correlated not
only in breast cancer patients but also in healthy females, but their
effect on breast cancer prognosis was opposite. Being overweight
or obese adversely affected DFS, but patients with high ALC had
better DFS than those with low ALC. After BMI/ALC risk
stratification, high-risk patients with high BMI/low ALC had
significantly worse DFS than low-risk patients.
Recent reports have suggested that obesity is a risk factor for
various metabolic diseases; it is also associated with the risk of
breast cancer. The Predicting Risk of Cancer at Screening
(PROCAS) study in United Kingdom found that weight gain in
adults is a risk factor for breast cancer, especially for those with
BMI < 23.4 kg/m2 at 20 years of age.14 Of the 47,042 non-breast
Table 2. Univariable and multi-variable Cox regression analysis
for DFS.
Univariable analysis Multi-variable analysis
HR (95% CI) P-value HR (95% CI) P-value
Age, yearsa 1.00 (0.99–1.02) 0.775
BMI, kg/m2
18.5–23.0 Ref. b Ref.
<18.5 0.76 (0.24–2.45) 0.644 0.50 (0.12–2.06) 0.334




ALC, ×103/uLa 0.52 (0.37–0.74) <0.001 0.43 (0.29–0.65) <0.001
ANC, ×103/uLa 1.06 (0.96–1.17) 0.270









Intermediate 1.51 (0.89–2.55) 0.128 0.94 (0.54–1.65) 0.831
High 2.03 (1.18–3.50) 0.011 0.85 (0.44–1.65) 0.625
Nuclear grade
Low Ref.
Intermediate 1.29 (0.64–2.60) 0.486
High 1.94 (0.96–3.91) 0.065
Oestrogen receptor
Negative Ref. Ref.
Positive 0.54 (0.38–0.78) 0.001 0.82 (0.46–1.49) 0.516
Progesterone receptor
Negative Ref. Ref.
Positive 0.54 (0.38–0.76) <0.001 0.89 (0.50–1.56) 0.678
HER2
Negative Ref. Ref.
Positive 1.59 (1.10–2.31) 0.015 1.19 (0.80–1.79) 0.388
Ki-67 LI, %
<14 Ref. Ref.
≥14 2.40 (1.67–3.45) <0.001 1.94 (1.22–3.07) 0.005
Tumour size, mm
≤20 Ref. Ref.
>20 2.12 (1.50–3.01) <0.001 1.47 (1.00–2.18) 0.050
Positive lymph node, count
0 Ref. Ref.
1–3 1.16 (0.77–1.76) 0.471 1.00 (0.65–1.55) 0.992
≥4 2.17 (1.27–3.73) 0.005 1.30 (0.72–2.34) 0.385
ALC absolute lymphocyte count, ANC absolute neutrophil count, BMI body
mass index, CI confidence interval, DFS disease-free survival, HER2 human
epidermal growth factor receptor 2, HR hazard ratio, LI labelling index, NLR
neutrophil-to-lymphocyte ratio, WBC white blood cell.
aContinuous variable.
bReference value.
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cancer patients followed up for a median of 5.6 years, 1142 were
diagnosed with breast cancer. Therefore, weight management is
important for preventing breast cancer and metabolic diseases,
such as diabetes and cardiovascular disease.
Body weight is also an important prognostic factor in breast
cancer patients. Chan et al. argued that obesity is associated with
poor OS and breast cancer-specific survival (BCSS) in breast cancer
patients in their systemic literature review of 82 follow-up
studies.15 In this meta-analysis, the relative risk (RR) of total
mortality in obese women was 1.75 and 1.34 for premenopausal
and postmenopausal breast cancer, respectively. Our study
findings were also similar to those of previous studies. In our
results, DFS of breast cancer patients is worse if BMI is high.
Unlike overweight or obese patients, prognosis of underweight
patients did not differ from normal-weight patients. Previous
studies in South Korea have reported that underweight women
may have risk factors for breast cancer such as early menarche and
nulliparity, leading to worse OS and BCSS.16,17 However, in our
study, underweight was not a risk factor for DFS and OS.
Additional investigations, including more numbers of under-
weight patients than our study, are needed since the proportion
of underweight patients in our cohort was very small.
The importance of immune responses in breast cancer is
gradually being recognised. Several studies have found that breast
tumours with high TILs have better prognosis than those with low
TILs. In addition, peripheral lymphocytes and neutrophils can
migrate toward a tumour site and infiltrate the tumour
microenvironment.18–21 Thus, research on immunologic markers
in peripheral blood, such as NLR, platelet-to-lymphocyte ratio
(PLR) and lymphocyte-to-monocyte ratio is being actively
conducted.22,23 However, there is a lack of data on ALC as a
prognostic marker in breast cancer. Although the reported
findings were discordant, previous studies have argued that ALC
can predict DFS and mortality.24,25 In addition, some researchers
have suggested that ALC is superior to NLR and PLR for predicting
progression-free survival in breast cancer.26 In our study, ALC was
a good predictor of DFS in breast cancer patients. Furthermore, we
demonstrated that ALC is more strongly associated with prognosis
than other blood parameters including NLR.
We divided the patients into two groups using the median ALC
(1.74 × 103/uL), which was consistent with the ALC reported in
previous studies (1.5–1.8 × 103/uL).24–26 However, lymphopenia is
defined as ALC < 1.0 × 103/uL, a much lower level; hence, low ALC





































Fig. 2 Kaplan–Meier survival curve for DFS according to the BMI/ALC risk stratification groups (log-rank P < 0.001). ALC absolute
lymphocyte count, BMI body mass index, DFS disease-free survival.
Table 3. Multi-variable Cox regression analysis for DFS using the BMI/
ALC risk stratification group.
HR (95% CI) P-value
BMI/ALC risk group
Low Ref. b
High 2.48 (1.70–3.62) <0.001
NLR, ×103/uLa 1.04 (0.98–1.10) 0.161
Histologic grade
Low Ref.
Intermediate 0.98 (0.56–1.71) 0.940
High 0.86 (0.44–1.67) 0.654
Oestrogen receptor
Negative Ref.
Positive 0.79 (0.43–1.43) 0.428
Progesterone receptor
Negative Ref.
Positive 0.95 (0.53–1.68) 0.855
HER2
Negative Ref.
Positive 1.17 (0.78–1.76) 0.450
Ki-67 LI, %
<14 Ref.
≥14 1.94 (1.22–3.07) 0.005
Tumour size, mm
≤20 Ref.
>20 1.46 (0.98–2.15) 0.060
Positive lymph node, count
0 Ref.
1–3 0.98 (0.63–1.53) 0.943
≥4 1.35 (0.75–2.43) 0.321
ALC absolute lymphocyte count, BMI body mass index, CI confidence
interval, DFS disease-free survival, HER2 human epidermal growth factor
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implications. Therefore, further research on new cut-off values that
can be used to demarcate low and high ALC for oncology studies
is needed. In addition, lymphocytes occasionally have opposing
functions. CD8+ cytotoxic T lymphocytes increase anti-tumour
immunity, and CD4+ helper T cells play critical roles in adaptive
immune response along with B lymphocytes and CD8+ cytotoxic
T cells.27–29 However, exhausted CD8+ T lymphocytes and
regulatory T cells (Treg; subset of CD4+ T lymphocyte) suppress
anti-tumour immunity.30,31 Therefore, the immune response to
breast tumour could vary depending on the composition of
lymphocytes, which ultimately affects prognosis. Further investi-
gation of the association between peripheral lymphocyte
composition and survival is needed.
To our knowledge, this is the first study to simultaneously
analyse BMI and ALC in breast cancer patients. Previous
experimental studies have suggested that obesity results in
hypertrophy of adipose tissue. The release of adipocytokines
leads to excessive immune cell recruitment with lymphocyte
predominance.12,32 Hypertrophic adipocytes increase the expres-
sion of pro-inflammatory cytokines and activate CD8+ cytotoxic T
lymphocytes and CD4+ helper T cells, but not Treg lymphocytes.
33
Our study demonstrated that these experimental results were
consistent with clinical observations in breast cancer patients. In
addition, the positive correlation between BMI and ALC was
reconfirmed in a large healthy population. Therefore, we
concluded that BMI and ALC are closely associated. Particularly,
the results regarding obesity and lymphocyte for healthy women
may be relevant to other fields of research. They may also be used
to determine the effect of BMI/ALC on breast cancer development
in further studies. Validation of the correlation between breast
cancer occurrence and BMI/ALC in normal population might
provide more specific information on the risk of breast cancer.
Our results suggest that increased BMI and ALC were not only
independent prognostic factors, but their effect on breast cancer
prognosis was opposite. ALC increased with the increasing BMI,
but patients with high BMI/low ALC had worse DFS than those
who did not. However, additional studies are necessary as the
association between obesity and immune response and mechan-
isms underlying the effect of BMI/ALC on breast cancer prognosis
are not fully understood.
Our study has some limitations. There was scope for selection
bias owing to its retrospective design. Since patients with
advanced breast cancer were usually treated with neoadjuvant
chemotherapy in our institution, most participants in our cohort
were early breast cancer patients. However, our finding that BMI
and ALC are risk factors for DFS even in early breast cancer with
a comparatively low recurrence rate may be meaningful. It was
difficult to accurately analyse the effect of underweight on
breast cancer prognosis owing to the small proportion of
underweight patients in our cohort. Peripheral inflammatory
cells can be affected by past history of patients including
chronic disease, alcohol consumption and smoking habit. Our
study did not take these variables into account. Analysing them
together in a future study could provide a clearer evidence for
the prevention of breast cancer. Furthermore, measuring obesity
using various techniques such as body fat measurement in
addition to BMI may helpful in evaluating the association
between breast cancer and obesity. Because body weight and
CBC data were recorded only at the time of diagnosis, serial
changes in these parameters could not be analysed. Thus, we
cannot ascertain if weight management after diagnosis is
related to breast cancer prognosis.
In conclusion, patients with high BMI/low ALC had worse DFS
than other groups. Therefore, these high-risk patients may require
more careful observation and aggressive treatment. Additional
studies are needed to delineate the underlying mechanisms by
which BMI/ALC affect breast cancer prognosis.
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